Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer
Honglu Ding,1,* Qiuxia Yang,2,* Yize Mao,1,* Dailei Qin,1 Zehui Yao,1 Ruiqi Wang,1 Tao Qin,3 Shengping Li1 1Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Can...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-03-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/serum-amyloid-a-predicts-prognosis-and-chemotherapy-efficacy-in-patien-peer-reviewed-fulltext-article-JIR |
| _version_ | 1797858318580973568 |
|---|---|
| author | Ding H Yang Q Mao Y Qin D Yao Z Wang R Qin T Li S |
| author_facet | Ding H Yang Q Mao Y Qin D Yao Z Wang R Qin T Li S |
| author_sort | Ding H |
| collection | DOAJ |
| description | Honglu Ding,1,* Qiuxia Yang,2,* Yize Mao,1,* Dailei Qin,1 Zehui Yao,1 Ruiqi Wang,1 Tao Qin,3 Shengping Li1 1Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People’s Republic of China; 2Department of Medical Imaging, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People’s Republic of China; 3Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shengping Li, Department of Pancreatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng Road E, Guangzhou, Guangdong, 510060, People’s Republic of China, Tel +86- 020-87341843, Email lishengp@mail.sysu.edu.cnPurpose: There is an urgent need to discover a predictive biomarker to help patients with advanced pancreatic cancer (APC) choose appropriate chemotherapy regimens. This study aimed to determine whether baseline serum amyloid A (SAA) levels were associated with overall survival (OS), progression-free survival (PFS), and treatment response in patients with APC received chemotherapy.Patients and Methods: This retrospective study included 268 patients with APC who received first-line chemotherapy at the Sun Yat-Sen University Cancer Center between January 2017 and December 2021. We examined the effect of baseline SAA on OS, PFS and chemotherapy response. The X-Tile program was used to determine the critical value for optimizing the significance of segmentation between Kaplan-Meier survival curves. The Kaplan-Meier curves and Cox regression analyses were used to analyze OS and PFS.Results: The best cut-off value of baseline SAA levels for OS stratification was 8.2 mg/L. Multivariate analyses showed that SAA was an independent predictor of OS (Hazard Ratio (HR) = 1.694, 95% Confidence Interval (CI) = 1.247– 2.301, p = 0.001) and PFS (HR = 1.555, 95% CI = 1.152– 2.098, p = 0.004). Low SAA was associated with longer OS (median, 15.7 months vs 10.0 months, p < 0.001) and PFS (median, 7.6 months vs 4.8 months, p < 0.001). The patients with a low SAA who received mFOLFIRINOX had longer OS (median, 28.5 months vs 15.1 months, p = 0.019) and PFS (median, 12.0 months vs 7.4 months, p = 0.035) than those who received nab-paclitaxel plus gemcitabine (AG) or SOXIRI, whereas there was no significant difference among the three chemotherapy regimens in patients with a high SAA.Conclusion: Owing to the rapid and simple analysis of peripheral blood, baseline SAA might be a useful clinical biomarker, not only as a prognostic biomarker for patients with APC, but also as a guide for the selection of chemotherapy regimens.Keywords: advanced pancreatic cancer, serum amyloid A, chemotherapy, prognosis, biomarker |
| first_indexed | 2024-04-09T21:11:27Z |
| format | Article |
| id | doaj.art-f3d488b52e6647d1906d06c63844a60e |
| institution | Directory Open Access Journal |
| issn | 1178-7031 |
| language | English |
| last_indexed | 2024-04-09T21:11:27Z |
| publishDate | 2023-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj.art-f3d488b52e6647d1906d06c63844a60e2023-03-28T18:02:01ZengDove Medical PressJournal of Inflammation Research1178-70312023-03-01Volume 161297131082538Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic CancerDing HYang QMao YQin DYao ZWang RQin TLi SHonglu Ding,1,* Qiuxia Yang,2,* Yize Mao,1,* Dailei Qin,1 Zehui Yao,1 Ruiqi Wang,1 Tao Qin,3 Shengping Li1 1Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People’s Republic of China; 2Department of Medical Imaging, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People’s Republic of China; 3Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shengping Li, Department of Pancreatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng Road E, Guangzhou, Guangdong, 510060, People’s Republic of China, Tel +86- 020-87341843, Email lishengp@mail.sysu.edu.cnPurpose: There is an urgent need to discover a predictive biomarker to help patients with advanced pancreatic cancer (APC) choose appropriate chemotherapy regimens. This study aimed to determine whether baseline serum amyloid A (SAA) levels were associated with overall survival (OS), progression-free survival (PFS), and treatment response in patients with APC received chemotherapy.Patients and Methods: This retrospective study included 268 patients with APC who received first-line chemotherapy at the Sun Yat-Sen University Cancer Center between January 2017 and December 2021. We examined the effect of baseline SAA on OS, PFS and chemotherapy response. The X-Tile program was used to determine the critical value for optimizing the significance of segmentation between Kaplan-Meier survival curves. The Kaplan-Meier curves and Cox regression analyses were used to analyze OS and PFS.Results: The best cut-off value of baseline SAA levels for OS stratification was 8.2 mg/L. Multivariate analyses showed that SAA was an independent predictor of OS (Hazard Ratio (HR) = 1.694, 95% Confidence Interval (CI) = 1.247– 2.301, p = 0.001) and PFS (HR = 1.555, 95% CI = 1.152– 2.098, p = 0.004). Low SAA was associated with longer OS (median, 15.7 months vs 10.0 months, p < 0.001) and PFS (median, 7.6 months vs 4.8 months, p < 0.001). The patients with a low SAA who received mFOLFIRINOX had longer OS (median, 28.5 months vs 15.1 months, p = 0.019) and PFS (median, 12.0 months vs 7.4 months, p = 0.035) than those who received nab-paclitaxel plus gemcitabine (AG) or SOXIRI, whereas there was no significant difference among the three chemotherapy regimens in patients with a high SAA.Conclusion: Owing to the rapid and simple analysis of peripheral blood, baseline SAA might be a useful clinical biomarker, not only as a prognostic biomarker for patients with APC, but also as a guide for the selection of chemotherapy regimens.Keywords: advanced pancreatic cancer, serum amyloid A, chemotherapy, prognosis, biomarkerhttps://www.dovepress.com/serum-amyloid-a-predicts-prognosis-and-chemotherapy-efficacy-in-patien-peer-reviewed-fulltext-article-JIRadvanced pancreatic cancerserum amyloid achemotherapyprognosisbiomarker. |
| spellingShingle | Ding H Yang Q Mao Y Qin D Yao Z Wang R Qin T Li S Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer Journal of Inflammation Research advanced pancreatic cancer serum amyloid a chemotherapy prognosis biomarker. |
| title | Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer |
| title_full | Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer |
| title_fullStr | Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer |
| title_full_unstemmed | Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer |
| title_short | Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer |
| title_sort | serum amyloid a predicts prognosis and chemotherapy efficacy in patients with advanced pancreatic cancer |
| topic | advanced pancreatic cancer serum amyloid a chemotherapy prognosis biomarker. |
| url | https://www.dovepress.com/serum-amyloid-a-predicts-prognosis-and-chemotherapy-efficacy-in-patien-peer-reviewed-fulltext-article-JIR |
| work_keys_str_mv | AT dingh serumamyloidapredictsprognosisandchemotherapyefficacyinpatientswithadvancedpancreaticcancer AT yangq serumamyloidapredictsprognosisandchemotherapyefficacyinpatientswithadvancedpancreaticcancer AT maoy serumamyloidapredictsprognosisandchemotherapyefficacyinpatientswithadvancedpancreaticcancer AT qind serumamyloidapredictsprognosisandchemotherapyefficacyinpatientswithadvancedpancreaticcancer AT yaoz serumamyloidapredictsprognosisandchemotherapyefficacyinpatientswithadvancedpancreaticcancer AT wangr serumamyloidapredictsprognosisandchemotherapyefficacyinpatientswithadvancedpancreaticcancer AT qint serumamyloidapredictsprognosisandchemotherapyefficacyinpatientswithadvancedpancreaticcancer AT lis serumamyloidapredictsprognosisandchemotherapyefficacyinpatientswithadvancedpancreaticcancer |